background
background
Earnings Expectation?
Beat
Meet
Miss
Expected Price Action?
Up
Flat
Down

Adial Pharmaceuticals, Inc. Beat Consensus Estimates

Thursday, May 15, 2025 at 8:30 AM ET

Adial Pharmaceuticals, Inc. (ADIL) reported a loss of $0.34 per share on revenue of $0.00 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.50 per share. The company beat consensus estimates by 32.00%.

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

Earnings Whisper Grade
Earnings Whisper GradeEarningsWhisper®edarG-
Power Rating
-
Reported Earnings
$-0.34
Earnings Whisper®
-
Consensus Estimate
$-0.50
Earnings Surprise
32.0%
Earnings Growth
50.0%
Reported Revenue
-
Revenue Estimate
-
Revenue Surprise
-
Revenue Growth